<p>在过去三个月中，5 位分析师对 SI-BONE（纳斯达克：SIBN）发布了评级，提供了从看涨到看跌的多样化观点。</p>
<p>下表提供了分析师最近评级的简要概述，展示了过去 30 天情绪变化的洞察，并与前几个月进行比较，以获得全面的视角。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>略微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>略微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师为 SI-BONE 设定了 12 个月的价格目标，显示出平均目标为 24.2 美元，最高预估为 27.00 美元，最低预估为 21.00 美元。当前的平均值反映出较之前的平均价格目标 22.75 美元增长了 6.37%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769522472_0_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769522472_0_0.png"/></p>
<h2>分析师评级探讨：深入概述</h2>
<p>通过对最近分析师行动的深入探讨，揭示了 SI-BONE 在金融专家中的地位。以下总结了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>宣布</td>
<td>买入</td>
<td>21.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>23.00 美元</td>
<td>21.00 美元</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>上调</td>
<td>买入</td>
<td>27.00 美元</td>
<td>26.00 美元</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>上调</td>
<td>买入</td>
<td>27.00 美元</td>
<td>24.00 美元</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>超配</td>
<td>23.00 美元</td>
<td>20.00 美元</td>
</tr>
</tbody>
</table>
<h3>关键洞察：</h3>
<ul>
<li><strong>采取的行动：</strong> 针对市场动态和公司表现的变化，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，都表明他们对 SI-BONE 相关最近发展的反应。这为分析师对公司当前状态的看法提供了洞察。</li>
<li><strong>评级：</strong> 提供对预测的洞察，分析师赋予定性值，从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了对 SI-BONE 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 分析师提供价格目标的洞察，给出对 SI-BONE 股票未来价值的估计。这种比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>通过理解这些分析师评估及相关财务指标，获取 SI-BONE 市场地位的宝贵洞察。保持信息灵通，利用我们的评级表做出战略决策。</p>
<p>随时了解 SI-BONE 分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>关于 SI-BONE 的所有信息</h2>
<p>SI-BONE Inc 是一家医疗设备公司，开发并商业化一种专有的微创外科植入系统，覆盖美国及国际市场。其产品包括一系列专利钛合金植入物及用于植入的仪器，以及可植入的骨产品，如 iFuse-3D、iFuse-TORQ 和 iFuse Bedrock Granite，这些产品在骶髂关节功能障碍与融合、成人脊柱畸形与退化以及骨盆创伤等方面有应用。</p>
<h3>SI-BONE：财务表现剖析</h3>
<p><strong>市值：</strong> 表明与行业平均水平相比规模较小，该公司的市值带来了独特的挑战。</p>
<p><strong>收入增长：</strong> 在过去 3 个月中，SI-BONE 表现积极，截至 2025 年 9 月 30 日，收入增长率为 <strong>20.61%</strong>。这反映了公司营业收入的显著增长。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> 公司的净利润率表现突出，超过行业平均水平。凭借 <strong>-9.38%</strong> 的净利润率，公司展现出强大的盈利能力和有效的成本控制。</p>
<p><strong>股本回报率（ROE）：</strong> SI-BONE 的财务实力体现在其卓越的 ROE 上，超过行业平均水平。ROE 达到 <strong>-2.67%</strong>，展示了资本的高效使用和强健的财务健康。</p>
<p><strong>资产回报率（ROA）：</strong> SI-BONE 的 ROA 超越行业基准，达到 <strong>-1.96%</strong>。这表明资产管理高效，财务健康状况良好。</p>
<p><strong>债务管理：</strong> 该公司保持平衡的债务策略，债务与股本比率低于行业标准，达到 <strong>0.21</strong>。</p>
<h2>分析师评级的重要性解析</h2>
<p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度对每只股票进行一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
<p>一些分析师还会提供增长预估、收益和收入等指标的预测，以进一步指导股票。使用分析师评级的投资者应注意，这些专业建议来自人类，可能会存在错误。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

SIBN

<p>在过去三个月中，五位分析师对 SI-BONE（NASDAQ:SIBN）进行了评级，显示出从看涨到看跌的情绪混合。12 个月的平均目标价为 24.2 美元，比之前的目标上涨了 6.37%。分析师们提高了他们的评级，其中 Truist Securities 和 Canaccord Genuity 等公司的增幅尤为显著。SI-BONE 报告的收入增长为 20.61%，净利润率为-9.38%。该公司还显示出强健的财务状况，债务与股本比率低至 0.21。分析师评级对投资者至关重要，反映了专家对股票表现的见解</p>

<p>In the last three months, 5 analysts have published ratings on SI-BONE (NASDAQ: SIBN), offering a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在过去三个月中，5 位分析师对 SI-BONE（纳斯达克：SIBN）发布了评级，提供了从看涨到看跌的多样化观点。</p>
</div><p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<div class="lb-trans"><p>下表提供了分析师最近评级的简要概述，展示了过去 30 天情绪变化的洞察，并与前几个月进行比较，以获得全面的视角。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>略微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>略微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for SI-BONE, revealing an average target of $24.2, a high estimate of $27.00, and a low estimate of $21.00. This current average reflects an increase of 6.37% from the previous average price target of $22.75.</p>
<div class="lb-trans"><p>分析师为 SI-BONE 设定了 12 个月的价格目标，显示出平均目标为 24.2 美元，最高预估为 27.00 美元，最低预估为 21.00 美元。当前的平均值反映出较之前的平均价格目标 22.75 美元增长了 6.37%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769522472_0_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769522472_0_0.png"/></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<div class="lb-trans"><h2>分析师评级探讨：深入概述</h2>
</div><p>The standing of SI-BONE among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的深入探讨，揭示了 SI-BONE 在金融专家中的地位。以下总结了关键分析师、他们的最新评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mathew Blackman</td>
<td>TD Cowen</td>
<td>宣布</td>
<td>买入</td>
<td>21.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>23.00 美元</td>
<td>21.00 美元</td>
</tr>
<tr>
<td>Caitlin Roberts</td>
<td>Canaccord Genuity</td>
<td>上调</td>
<td>买入</td>
<td>27.00 美元</td>
<td>26.00 美元</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>上调</td>
<td>买入</td>
<td>27.00 美元</td>
<td>24.00 美元</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>超配</td>
<td>23.00 美元</td>
<td>20.00 美元</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键洞察：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to SI-BONE. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SI-BONE compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of SI-BONE's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 针对市场动态和公司表现的变化，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，都表明他们对 SI-BONE 相关最近发展的反应。这为分析师对公司当前状态的看法提供了洞察。</li>
<li><strong>评级：</strong> 提供对预测的洞察，分析师赋予定性值，从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了对 SI-BONE 相对于更广泛市场的相对表现的预期。</li>
<li><strong>价格目标：</strong> 分析师提供价格目标的洞察，给出对 SI-BONE 股票未来价值的估计。这种比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>Capture valuable insights into SI-BONE's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<div class="lb-trans"><p>通过理解这些分析师评估及相关财务指标，获取 SI-BONE 市场地位的宝贵洞察。保持信息灵通，利用我们的评级表做出战略决策。</p>
</div><p>Stay up to date on SI-BONE analyst ratings.</p>
<div class="lb-trans"><p>随时了解 SI-BONE 分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>All You Need to Know About SI-BONE</h2>
<div class="lb-trans"><h2>关于 SI-BONE 的所有信息</h2>
</div><p>SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.</p>
<div class="lb-trans"><p>SI-BONE Inc 是一家医疗设备公司，开发并商业化一种专有的微创外科植入系统，覆盖美国及国际市场。其产品包括一系列专利钛合金植入物及用于植入的仪器，以及可植入的骨产品，如 iFuse-3D、iFuse-TORQ 和 iFuse Bedrock Granite，这些产品在骶髂关节功能障碍与融合、成人脊柱畸形与退化以及骨盆创伤等方面有应用。</p>
</div><h3>SI-BONE: Financial Performance Dissected</h3>
<div class="lb-trans"><h3>SI-BONE：财务表现剖析</h3>
</div><p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<div class="lb-trans"><p><strong>市值：</strong> 表明与行业平均水平相比规模较小，该公司的市值带来了独特的挑战。</p>
</div><p><strong>Revenue Growth:</strong> Over the 3M period, SI-BONE showcased positive performance, achieving a revenue growth rate of <strong>20.61%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> 在过去 3 个月中，SI-BONE 表现积极，截至 2025 年 9 月 30 日，收入增长率为 <strong>20.61%</strong>。这反映了公司营业收入的显著增长。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-9.38%,</strong> the company showcases strong profitability and effective cost control.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> 公司的净利润率表现突出，超过行业平均水平。凭借 <strong>-9.38%</strong> 的净利润率，公司展现出强大的盈利能力和有效的成本控制。</p>
</div><p><strong>Return on Equity (ROE):</strong> SI-BONE's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-2.67%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> SI-BONE 的财务实力体现在其卓越的 ROE 上，超过行业平均水平。ROE 达到 <strong>-2.67%</strong>，展示了资本的高效使用和强健的财务健康。</p>
</div><p><strong>Return on Assets (ROA):</strong> SI-BONE's ROA excels beyond industry benchmarks, reaching <strong>-1.96%</strong>. This signifies efficient management of assets and strong financial health.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> SI-BONE 的 ROA 超越行业基准，达到 <strong>-1.96%</strong>。这表明资产管理高效，财务健康状况良好。</p>
</div><p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.21</strong>.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> 该公司保持平衡的债务策略，债务与股本比率低于行业标准，达到 <strong>0.21</strong>。</p>
</div><h2>The Significance of Analyst Ratings Explained</h2>
<div class="lb-trans"><h2>分析师评级的重要性解析</h2>
</div><p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<div class="lb-trans"><p>评级来自分析师，或在银行和金融系统内的专家，他们为特定股票或定义的行业报告（通常每季度对每只股票进行一次）。分析师通常从公司电话会议和会议、财务报表以及与重要内部人士的对话中获取信息，以做出决策。</p>
</div><p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<div class="lb-trans"><p>一些分析师还会提供增长预估、收益和收入等指标的预测，以进一步指导股票。使用分析师评级的投资者应注意，这些专业建议来自人类，可能会存在错误。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

通过五位分析师的视角，了解对 SI-BONE 的专家展望